Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study
Wouter Froyman(Rega Institute for Medical Research), D. Timmerman(Rega Institute for Medical Research), S. Guerriero(University of Cagliari), A. C. Testa(Università Cattolica del Sacro Cuore), E. Epstein(Karolinska Institutet), T. Bourne(Luigi Sacco Hospital), Francesco Leone(Istituto Oncologico Veneto), Juan Luis Alcázar(Universidad de Navarra), Marek Kudła(Medical University of Silesia), Lauri Hochberg(University of South Florida), L. Valentin(Malmö University), Ignace Vergote(KU Leuven), Jan Y. Verbakel(University of Oxford), P. Sladkevicius(Lund University), Robert Fruscio(Azienda Ospedaliera San Gerardo), C. Landolfo(Queen Charlotte's and Chelsea Hospital), L. Jokubkiene(Lund University), An Coosemans(KU Leuven), Laure Wynants(Maastricht University), Nandita Deo(Whipps Cross University Hospital), D. Franchi(European Institute of Oncology), J. Kaijser(KU Leuven), F. Buonomo(IRCCS Materno Infantile Burlo Garofolo), Valentina Chiappa(Fondazione IRCCS Istituto Nazionale dei Tumori), Ben Van Calster(University Medical Center Utrecht), Maria Elisabetta Coccia(University of Florence), Maria José Bernardo(Unidade Local de Saúde de São José), Caroline Van Holsbeke(Ziekenhuis Oost-Limburg), Ekaterini Domali(National and Kapodistrian University of Athens)
Cited by 188
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k